The deal boosts Ipsen’s commercial presence while returning Merrimack to a clinical-stage biotech. ShareFacebookTwitterLinkedInEmailPrint Merrimack Pharmaceuticals has agreed to sell cancer drug Onivyde and other assets to Ipsen for $575 million in cash upfront, turning Merrimack […]